A Phase 2 Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer’s Disease. The study medication is an OGA Inhibitor which slows the accumulation of hyperphosphorylated tau (oral), a key driver of worsening Alzheimer’s tangle pathology.

Eligibility includes:
Age 60-85
Participants must have gradual and progressive changes in memory for at least 6 months
Have a study partner who will provide written informed consent to participate

    Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.